The short answer
IGF-1 has no PubChem record because proteins of this size are indexed in sequence databases such as UniProt rather than small-molecule databases. The native sequence is UniProt P05019. LR3 is an engineered analogue and has no database record of its own.
Key facts
- PubChem record
- None (expected for a protein)
- Native IGF-1
- UniProt P05019
- Precursor
- 195 residues, 21,841 Da
- Mature native
- 70 residues, ~7.6 kDa
- LR3 database record
- None (engineered analogue)
- Best available check
- Certificate plus mass and purity data
Why there is no PubChem entry
PubChem indexes small molecules. Proteins live in sequence databases. UniProt for curated sequence records, the PDB for structures. IGF-1's absence from PubChem is therefore expected and unremarkable, which distinguishes it sharply from retatrutide's absence, where a compound of small-molecule scale should be there and is not.
What UniProt gives you
P05019 is the human IGF-1 entry, recording a 195-residue precursor at 21,841 Da. The mature circulating hormone is the 70-residue product of processing that precursor, so the number in the database is not the number on a certificate, and knowing why is necessary to read either correctly.
Research material referenced
IGF-1 LR3 1mg, third-party HPLC tested
Why LR3 has no record at all
Sequence databases catalogue naturally occurring proteins and their variants. An engineered analogue with a synthetic N-terminal extension is a designed molecule, not a gene product, so it has no entry to look up. Verification therefore rests entirely on the supplier's documentation.
What a certificate should carry
Sequence as stated. Mass by mass spectrometry, matching the stated sequence. Purity by HPLC with a chromatogram. Host cell protein and host DNA. Endotoxin, with its own assay. And ideally something addressing conformation or biological activity, since none of the preceding tests can confirm the protein is folded.
The check that is missing from most certificates
Activity. Everything else is chemistry, and for a molecule whose function is entirely conformational, chemistry is necessary but not sufficient. A cell-based or receptor-binding assay is the only test that speaks to whether the protein works, and its absence is the most common gap in documentation for this class.
Frequently asked questions
Why is IGF-1 not in PubChem?
PubChem indexes small molecules. Proteins are catalogued in UniProt and the PDB. Its absence is expected.
What is UniProt P05019?
The human IGF-1 entry. A 195-residue precursor at 21,841 Da, processed to the 70-residue mature hormone.
How do I verify LR3 itself?
There is no database record for an engineered analogue. Verification rests on the certificate: sequence, mass, purity, host cell protein, host DNA and endotoxin.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More IGF-1 LR3 articles
- IGF-1 LR3 and Anti-Doping StatusIGF-1 and its analogues sit in WADA class S2, prohibited in and out of competition. What that classification covers and why it is unconditional.
- IGF-1 LR3 Regulatory StatusNo marketing authorisation anywhere, though an approved native rhIGF-1 exists. Why that distinction is the important one in this category.
- A Natural Experiment in Absent IGF-1People with growth hormone receptor deficiency produce almost no IGF-1. Laron and Werner report that they do not develop cancer.
- A Strong Rationale That Did Not TranslateThe IGF-1 receptor was pursued as an oncology target on excellent biological grounds. The clinical programmes largely failed, and why is instructive.
- A Regulatory System, Deliberately EvadedIGF binding proteins restrain IGF-1 availability. LR3 exists to escape them. Set against the Laron findings, that is worth stating plainly.